Abstract

BackgroundThe introduction of biosimilar drugs into clinical practice allows us to maintain the effectiveness and safety of treatments, taking greater advantage of health resourcesPurposeThe objective of the study was to...

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Infliximab Biosimilar
  • Rheumatological Pathology
  • Use Of Biosimilar Medicines
  • Treatment Of Inflammatory Bowel Disease
  • Inflammatory Bowel Disease
    • + Show 5 more

Create a personalized feed of these topics

Get Started
Discovery Logo

Access 100M+ research papers and stay updated

  • Largest bank of Open Access content (40 MN OA papers incl. 2M pre-prints)
  • Content across 9.5M topics & 32K+ academic journals
  • 10K new papers added every day
It’s FREE. Sign Up Now!

Similar Papers

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
  • Journal of Clinical Pharmacy and Therapeutics
  • Sep 22, 2022
Relevant
Not Relevant
[New molecules in the treatment of inflammatory bowel disease].
  • Gastroenterología y Hepatología
  • Jan 1, 2016
Relevant
Not Relevant
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
  • Expert Opinion on Biological Therapy
  • Feb 1, 2022
Relevant
Not Relevant
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
  • Alimentary Pharmacology & Therapeutics
  • Nov 1, 2001
Relevant
Not Relevant
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
  • Journal of Crohn's and Colitis
  • Aug 1, 2013
Relevant
Not Relevant
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases
  • Alimentary Pharmacology & Therapeutics
  • Feb 26, 2017
Relevant
Not Relevant
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
  • Journal of Gastroenterology and Hepatology
  • Nov 24, 2015
Relevant
Not Relevant
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
  • Therapeutic Advances in Gastroenterology
  • Nov 11, 2014
Relevant
Not Relevant
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
  • Indian Journal of Gastroenterology
  • Oct 1, 2022
Relevant
Not Relevant
The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine
  • Alimentary Pharmacology & Therapeutics
  • Nov 6, 2001
Relevant
Not Relevant
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
  • Frontiers in Pharmacology
  • May 31, 2017
Relevant
Not Relevant
Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation
  • Terapevticheskii arkhiv
  • Aug 15, 2019
Relevant
Not Relevant
Comparison of original and biosimilar infliximab (CTP-13) in biologic-na�ve patients with Crohn�s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain.
  • Revista Española de Enfermedades Digestivas
  • Jan 1, 2020
Relevant
Not Relevant
Сучасні підходи до лікування запальних захворювань кишечника в дітей відповідно до останніх рекомендацій Європейської організації з вивчення хвороби Крона і коліту, Європейського товариства дитячих гастроентерологів, гепатологів та нутриціологів
  • Modern pediatrics. Ukraine
  • Mar 27, 2021
Relevant
Not Relevant
5PSQ-071\u2005Evaluation of the effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease
  • European Journal of Hospital Pharmacy
  • Mar 1, 2019
Relevant
Not Relevant
READ MORE FROM

European Journal of Hospital Pharmacy